Alzeca Biosciences raised $11 million to develop its nanoparticle contrast agent, designed for the early detection of Alzheimer’s disease.

VentureMed Group raised $15 million to support R&D, clinical trials and expand the sales team for its PAD treatment catheter.

Consultancy-cum-VC Genesis Innovation has raised cash to back medical device startups.

NeoSync raised $13 million for a registration trial of its magnetic stimulation technology in treatment-resistant depression.

Neuros Medical raised $20 million to complete the pivotal study of its neuromodulation device for postamputation pain.

Karius raised $50 million to boost clinical trials and commercialization of its blood-based test that detects more than 1,250 pathogens.

Viome raised $15 million for its microbiome-sequencing platform, which uses machine learning to help patients avoid chronic disease.

Sebacia raised $36 million to complete the U.S. pivotal trial of its gold-and-silica microparticle acne treatment.

The series B round equips Amphora to take its minimally invasive, cystoscopic device into the last step of clinical development next year.